文献速递淋巴瘤造血干细胞移植与细胞治疗

英国接受CD19 CAR T治疗的大B细胞淋巴瘤患者放疗桥接的结局与可行性

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
PubMed 文献 · Br J Haematol · 2024-04-09

该多中心全国队列分析了12个英国中心获批接受三线阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤患者中放疗桥接的使用情况。717例有桥接数据的患者中169例(24%)接受放疗桥接,单模态129例、联合模态40例;单模态1年无进展生存率为56%,联合模态为47%,全身桥接为43%。作者认为放疗桥接即使在高危晚期疾病中也可安全有效使用,脱组率低且结局良好。

要点

  • 717例有桥接数据的患者中169例(24%)接受放疗桥接,其中单模态129例、联合模态40例。
  • 放疗桥接患者1年无进展生存率:单模态56%、联合模态47%,全身桥接为43%。
  • 各中心放疗桥接使用率介于11%至32%之间,并随时间增加。

核心结论

  • 放疗桥接即使在高危晚期疾病中也可安全有效使用,脱组率低且结局良好。
  • 这是迄今报道的最大规模接受CAR T前放疗桥接的大B细胞淋巴瘤患者队列。

研究设计与样本

  • 多中心全国队列,纳入英国12个中心获批接受三线阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤患者。
  • 763例获批患者中722例接受了白细胞分离,717例有桥接治疗数据。

主要发现

  • 169/717(24%)接受放疗桥接,其中129例为单模态、40例为联合模态治疗(CMT)。
  • 169例放疗桥接患者中,65.7%为晚期、36.9%有大包块、86.5%乳酸脱氢酶升高、41.7%国际预后指数(IPI)≥3、15.2%为双打击/三打击。
  • 放疗桥接使用率各中心介于11%至32%之间,并随时间增加。
  • 静脉到静脉时间和输注率在不同桥接方式间无差异。
  • 放疗桥接患者结局良好:单模态1年无进展生存率56%,联合模态47%,全身桥接为43%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B-cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT). Of 169 patients, 65.7% had advanced stage, 36.9% bulky disease, 86.5% elevated LDH, 41.7% international prognostic index (IPI) ≥3 and 15.2% double/triple hit at the time of approval. Use of RT bridging varied from 11% to 32% between centres and increased over time. Vein-to-vein time and infusion rate did not differ between bridging modalities. RT-bridged patients had favourable outcomes with 1-year progression-free survival (PFS) of 56% for single modality and 47% for CMT (1-year PFS 43% for systemic bridging). This is the largest cohort of LBCL patients receiving RT bridging prior to CAR T reported to date. Our results show that RT bridging can be safely and effectively used even in advanced stage and high-risk disease, with low dropout rates and excellent outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kuhnl A, Roddie C, Kirkwood AA, et al. Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. Br J Haematol. 2024. PMID: 38594876. doi:10.1111/bjh.19453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。